Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy

NCT00039910 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00039910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00039910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2000
Completion date
March 31, 2003
Enrollment
240
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, non-hodgkin lymphoma, thrombocytopenia